ZHAOKE OPHTH-B (06622) continued its upward momentum with gains exceeding 7%. As of press time, the stock was up 6.48% to HK$4.27, with trading volume reaching HK$10.876 million.

On the news front, ZHAOKE OPHTH-B announced that the company has entered into a distribution and supply agreement with leading Indonesian pharmaceutical company PT Ferron Par Pharmaceuticals for the Indonesian market. The agreement covers the company's core product - atropine sulfate eye drops (NVK002), which is used to slow myopia progression in children and adolescents.

Under the terms of the agreement, ZHAOKE OPHTH-B has granted PT Ferron exclusive rights to import, promote, distribute, market and sell the product in Indonesia. ZHAOKE OPHTH-B will receive an upfront payment and is eligible for additional milestone payments based on certain achievements.

Additionally, earlier this year, ZHAOKE OPHTH-B's abbreviated new drug application for the 0.01% dose of atropine sulfate eye drops and new drug application for the 0.02% dose have been successively accepted by China's National Medical Products Administration and are currently under review.